Cat with CKD: The power of SGLT2 inhibitors: the breakthrough in kidney disease Human/veterinary comparison

Studies on Velagliflozin and Bexagliflozin Renal Impairment in Cats

After 15 days of full immersion in research, I published the first article in Italy on the incredible power of SGLT2 inhibitors against chronic kidney disease. I sifted through several molecules, including those approved by the FDA. Find out how things are changing.

The use of velagliflozin, an SGLT2 inhibitor, has been studied in diabetic cats, and there is evidence exploring its safety and efficacy, particularly in patients with kidney failure.

1. Sicurezza ed efficacia nei Gatti Diabetici :
   • Velagliflozin was administered to diabetic cats at a dose of 1 mg/kg orally once daily. Clinical trials have shown that the drug can reduce blood glucose levels consistently and reliably, bringing significant clinical improvements.
   • In a European clinical trial, treatment with velagliflozin led to a combined improvement in diabetes-related clinical signs and laboratory glycemic parameters, showing a success rate of 53.7% compared to insulin treatment.
2. Considerazioni sull’insufficienza renale :
   • In patients with renal impairment, regular assessment of renal function, body weight and hydration status is recommended. Studies have included cats with IRIS stage 1 and 2 kidney disease, suggesting that velagliflozin can also be used in these cases, but with caution.
   • It is important to monitor cats for signs of dehydration or other interference related to kidney function during treatment.
3. Effetti Collaterali :
   • Common side effects associated with velagliflozin use include diarrhea (37.7%) and bladder inflammation (21.3%). Although asymptomatic hypoglycemia was observed in 13.1% of treated cats, a higher incidence of clinical hypoglycemia was not reported compared to the insulin-treated group.
4. Meccanismo d’azione :
   • Velagliflozin works by inhibiting SGLT2 in the kidney, increasing urinary excretion of glucose and thus contributing to the reduction of blood sugar. This mechanism is particularly useful in diabetic cats, where glycemic control is crucial.

Conclusion

In summary, velagliflozin shows promise in treating diabetes in cats, including those with kidney failure. However, it is crucial to closely monitor kidney function and manage pre-existing conditions. Clinical studies suggest that velagliflozin may be an effective and well-tolerated treatment option for diabetic cats.

(Veterinary) Bexagliflozin and renal failure: Clinical Studies

Bexagliflozin (brand name Bexacat) manufactured by Elanco Animal Health is a type 2 sodium-glucose co-transporter (SGLT2) inhibitor that has shown promise in the management of type 2 diabetes and its complications, including kidney failure.

• Bexagliflozin: Recent studies have indicated that bexagliflozin reduces the risk of cardiovascular events, including cardiovascular mortality and hospitalizations for heart failure.
• Dapagliflozin and Empagliflozin: Both showed significant cardiovascular benefits, with empagliflozin in particular demonstrating a reduction in cardiovascular mortality by 38% and heart failure hospitalizations by 35% in the EMPA-REG OUTCOME study.

3. Impact on Kidney Disease Progression

• Bexagliflozin: Shown to slow the progression of CKD, reducing glomerular filtration rate loss (eGFR) and albuminuria.
• Dapagliflozin and Empagliflozin: These drugs also showed positive effects on kidney function, contributing to a significant reduction in the risk of renal adverse events.

4. Security Profile

• Bexagliflozin: Exhibits a favorable safety profile, with manageable side effects similar to those seen with other SGLT2i.
• Dapagliflozin and Empagliflozin: They also have a good safety profile, but may pose risks such as hyperkalaemia and urinary infections.

Conclusion

Bexagliflozin has demonstrated similar benefits to dapagliflozin and empagliflozin in terms of glycemic control, cardiovascular protection, and management of kidney disease. These findings suggest that bexagliflozin may be an effective treatment option for patients with type 2 diabetes and CKD, helping to improve overall outcomes. However, further clinical trials are needed to confirm these findings and optimize therapeutic strategies.

1. Efficacia Nefroprotettiva :
   • Clinical studies have shown that bexagliflozin may reduce the risk of kidney disease progression in diabetic patients. Its nephroprotective action is similar to that of other SGLT2 inhibitors, helping to slow the decline in glomerular filtration rate (eGFR) and improve markers of kidney damage such as albuminuria.
2. Studi Clinici :
   • Although there are no specific published results on bexagliflozin in patients with renal impairment, the general evidence on SGLT2i suggests that the class of drugs to which bexagliflozin belongs is effective in improving renal outcomes. For example, studies of dapagliflozin and empagliflozin shown to have significant reductions in kidney disease progression and cardiovascular mortality.
3. Sicurezza nei pazienti con insufficienza renale :
   • SGLT2 inhibitors, including bexagliflozin, are generally well tolerated, but their efficacy may decrease in patients with severe renal impairment. It is important to monitor renal function during treatment and to adjust doses when necessary.
4. Raccomandazioni Cliniche :
   • International guidelines recommend the use of SGLT2i for the management of chronic kidney disease, highlighting the benefits in slowing disease progression and improving cardiovascular outcomes. The safety and efficacy of bexagliflozin in patients with renal impairment require further clinical studies to confirm preliminary results.

Summary of the Use of SGLT2 Inhibitors in Renal Failure

1. Cardiovascular and Renal Benefits

• SGLT2i, like empagliflozin and dapagliflozin , showed a protective effect on both renal function and cardiovascular health. Recent studies indicate that the use of these drugs is associated with a significant reduction in mortality and renal adverse events and benefit in patients with type 2 diabetes and acute renal failure.
• For example, a study of over 10,000 patients showed that the use of SGLT2i leads to a reduction in the risk of mortality (AHR 0.69) and adverse renal events (AHR 0.62).

2. Specific Evidence for Empagliflozin

• The EMPA-KIDNEY study demonstrated that empagliflozin is effective in slowing the progression of kidney disease and reducing cardiovascular mortality, with a 28% relative risk reduction compared to placebo, regardless of the presence of diabetes3.

3. Evidence for Dapagliflozin

• The DAPA-CKD study confirmed that dapagliflozin reduces the risk of kidney disease progression in patients with chronic renal failure, showing positive effects even in non-diabetic patients.

Best Molecule for Renal Failure

Currently, empagliflozin and dapagliflozin are considered the best SGLT2 inhibitors for use in patients with renal impairment, due to their extensive clinical data supporting their efficacy in improving renal and affective outcomes.

• Empagliflozin : Efficacy in patients with advanced renal impairment (up to eGFR of 20 mL/min) and associated with a significant reduction in cardiovascular mortality.
• Dapagliflozin : Demonstrated a similar efficacy profile, with positive results in renal and cardiovascular protection.

Use in Veterinary

Dapagliflozin has been the subject of clinical studies in animals, in particular to evaluate its efficacy in the treatment of hyperglycemia and its impact on various metabolic parameters. Here is a summary of the available evidence:

Clinical Studies on Dapagliflozin in Animals

1. Effetti Metabolici nei Topi db/db :
   • One study showed that treatment with dapagliflozin (Dapa) in db/db animals (a model of diabetes) reduced both fasted and non-fasting hyperglycemia by increasing insulin levels and the area of pancreatic islets. This suggests a positive effect on pancreatic function and glycemic control.
2. Analisi di Metabolomica :
   • Metabolomic plasma analysis showed significant differences in metabolic profiles between the dapagliflozin-treated and control groups. In particular, the treatment led to an enrichment of tryptophan metabolites, which are related to the production of glucagon-like peptide-1 (GLP-1), suggesting a mechanism of action involving the gut microbiota and the GLP-1 signaling pathway.
3. Tossicità nei Modelli Animali :
   • Other studies have examined the toxicity of dapagliflozin in juvenile rats, showing effects on renal development during critical stages of pregnancy in animal models. These data are important for understanding the safety of the drug in clinical settings.
4. Sicurezza e Tollerabilità :
   • Animal clinical studies have also evaluated the tolerability of dapagliflozin, with results indicating good overall safety, similar to that observed in human clinical trials.

Conclusion

Dapagliflozin has demonstrated positive effects in the treatment of hyperglycemia in diabetic animal models, with evidence suggesting complex mechanisms related to gut microbiota and hormonal regulation. However, specific studies of dapagliflozin in veterinary medicine are limited compared to those conducted in humans.

There are a few recent studies testing the effects of SGLT2 inhibitors in cats. The study of bexagliflozin in cats found a significant reduction in insulin requirements and a decrease in blood sugar and fructosamine, all without hypoglycemia. On December 8, 2022, the FDA approved the first oral animal medication to improve glycemic control in cats with diabetes mellitus not previously treated with insulin. Bexagliflozin is also the first SGLT2 inhibitor drug for animals approved by the FDA. On August 14, 2023, the FDA approved the first oral liquid drug for the treatment of diabetes in cats; velagliflozin oral solution (Senvelgo; Boehringer Ingelheim) is a once-daily treatment administered into food or directly into the cat’s mouth.

Sodium-glucose co-transporter type 2 inhibitors: will these drugs be useful to non-diabetic veterinary patients suffering from heart and kidney disease?

Sodium-glucose co-transporter type 2 (SGLT2) inhibitors are drugs used in human medicine primarily for blood sugar control in diabetes. However, recent clinical trials have shown benefits that go beyond reducing blood sugar, including protective effects on the heart and kidneys, in both diabetic and non-diabetic patients. Conditional approval for use in diabetic cats and use in other animal species have raised the question of whether such cardioprotective and nephroprotective effects can also occur in non-diabetic dogs and cats. Current research focuses on identifying the mechanisms underlying these effects and defining the categories of non-diabetic veterinary patients who could benefit the most from this class of drugs.

Veterinary: study published on July 13, 2024 for those who want to learn more or if this summary of mine was unclear 😉 You can consult an additional text at the following link

Veterinary: Study published April 30, 2024: Effect of Sodium-Glucose Co-transporter Inhibitor Type 2, DWP16001, as an Adjunctive Therapy to Insulin for Diabetic Dogs: A Pilot Study

SGLT2 and Renal Failure: An In-Depth Analysis in HUMAN

Sodium-glucose co-transporter type 2 (SGLT2) inhibitors represent an innovative class of drugs used primarily in the treatment of type 2 diabetes. Recently, their application has also extended to the management of kidney failure, thanks to their nephroprotective effects and ability to improve kidney function. This article will explore the mechanism of action of SGLT2, their effects on renal failure, and clinical implications.

Mechanism of Action of SGLT2

SGLT2 are proteins located in the proximal tubule of the kidney, responsible for the reabsorption of about 90% of filtered glucose. SGLT2 inhibitors block this reabsorption, leading to increased urinary glucose excretion (glycosuria) and reduced blood glucose levels. This mechanism is particularly useful in diabetic patients, as it helps to improve glycemic control without depending on insulin.

Nephroprotective effects

Numerous studies have shown that SGLT2 not only improves glycemic control but also offers significant benefits for kidney health. These nephroprotective effects are attributed to several mechanisms:

1. Reduction of Glomerular Hyperfiltration: Inhibition of SGLT2 leads to less hyperfiltration at the glomerular level, a factor that contributes to the decline of kidney function in diabetic patients. This is done through a tubuloglomerular feedback mechanism that improves renal hemodynamics.
2. Effects on Blood Pressure: SGLT2 reduces systemic blood pressure through increased natriuresis (sodium elimination) and reduction in intravascular volume, further contributing to renal protection.
3. Reduced blood sugar and body weight: These drugs also aid in weight loss, a factor that can further improve kidney function in patients with diabetes.

Clinical implications

The use of SGLT2 has been associated with a significant reduction in the progression of renal failure and an improvement in cardiovascular outcomes in diabetic patients. Recent studies have shown that treatment with SGLT2 can slow the progression of chronic kidney disease (CKD) and reduce the risk of adverse cardiovascular events. However, it is important to consider the contraindications and potential side effects associated with the use of these medications, such as the risk of urinary and genital infections and acute kidney failure in some patients with impaired kidney function.

What are the specific benefits of SGLT2i for patients with renal impairment

1. Reduction of Progression of Kidney Disease

Recent studies have shown that SGLT2i can significantly reduce the progression of chronic kidney disease (CKD). A meta-analysis showed that treatment with SGLT2i leads to a reduction in kidney disease progression of up to 37% compared to placebo, measured as a reduction in glomerular filtration rate (GFR) of more than 50%, entry to dialysis or death from renal causes. This effect has been observed in both diabetic and non-diabetic patients.

2. Cardiovascular Protection

In addition to kidney benefits, SGLT2i has shown positive effects on cardiovascular health. These drugs reduce the risk of cardiovascular death and hospitalizations for heart failure by 23%. This is particularly relevant since many patients with renal impairment also have cardiovascular comorbidities.

3. Reduction of Acute Renal Failure

The use of SGLT2i is associated with a 23% decrease in the risk of acute renal failure. This is an important finding, considering that acute kidney failure can further complicate the management of patients with chronic kidney disease.

4. Improved Nephrotic Function

SGLT2i improve nephrotic function through mechanisms such as reduction of glomerular hyperfiltration and improvement of tubuloglomerular feedback. These effects contribute to greater stability of kidney function, reducing the risk of progressive kidney damage.

5. Positive metabolic effects

These drugs not only lower blood glucose levels through increased urinary excretion of glucose, but also contribute to weight loss and reduced blood pressure. These effects are particularly beneficial for patients with kidney failure, as obesity and hypertension are significant risk factors for kidney disease progression.

6. Security and Adverse Profile

SGLT2i has a generally positive safety profile, with a low incidence of serious adverse events. Although there are concerns regarding possible side effects such as urinary and genital infections, these risks are considered manageable in most patients.

What are the main recent studies of SGLT2i for renal impairment

In recent years, sodium-glucose co-transporter type 2 inhibitors (SGLT2i) have been shown to have significant effects not only in the treatment of type 2 diabetes, but also in the management of kidney failure. Below are the main recent studies that highlight the effectiveness of these drugs in kidney protection.

1. EMPA-KIDNEY Study

One of the most relevant recent studies is the EMPA-KIDNEY study, published in the New England Journal of Medicine. This study enrolled patients with chronic kidney disease, regardless of the presence of diabetes, and showed that treatment with empagliflozin significantly reduced the progression of kidney disease and the risk of death from cardiovascular causes. The results showed a 28% reduction in relative risk compared to placebo for kidney disease progression or cardiovascular death. In addition, a significant decrease in all-cause hospitalizations was observed, with a relative risk reduction of 14%.

2. Meta-analysis on SGLT2i

A meta-analysis of 13 clinical trials confirmed that SGLT2i reduced renal disease progression (defined as a reduction in GFR greater than 50%, entry into dialysis, or death from renal causes) by 37% compared to placebo. This effect was observed in both diabetic and non-diabetic patients and regardless of the type of kidney disease. In addition, a 23% reduction in the risk of acute kidney failure was recorded.

3. DAPA-CKD Study

Another significant study is the DAPA-CKD, which examined the efficacy of dapagliflozin in patients with chronic kidney disease. The results showed that dapagliflozin significantly reduced the risk of renal and cardiovascular adverse events, confirming the efficacy of SGLT2i in slowing the progression of kidney disease in a non-diabetic population.

4. Cardiovascular and Renal Outcomes

In addition to nephroprotective effects, SGLT2i has been shown to have a positive impact on cardiovascular health. SGLT2i therapy led to a significant reduction in cardiovascular mortality and heart failure hospitalizations, with a 23% reduced risk for both outcomes. These findings are particularly relevant for patients with renal impairment, who often have cardiovascular comorbidities.

5. Clinical Recommendations

Recent international guidelines recommend the use of SGLT2i as a first-line treatment for patients with chronic kidney disease, emphasizing their importance in preventing disease progression and improving cardiovascular outcomes. The recommendations of the KDIGO 2024 guidelines highlight the use of SGLT2i in patients with chronic renal failure, regardless of the presence of diabetes.

Conclusion

SGLT2 inhibitors are emerging as a key therapeutic class in the management of renal failure, due to their ability to slow disease progression and improve cardiovascular outcomes. The results of recent studies strongly support the integration of these drugs into clinical practice for patients suffering from chronic kidney disease.

What are the most recent results of the EMPA-KIDNEY6 study

The most recent results from the EMPA-KIDNEY study highlighted the efficacy of the SGLT2 inhibitor empagliflozin in the treatment of chronic kidney disease, showing significant benefits on both renal function and cardiovascular mortality.

Key Results of the EMPA-KIDNEY Study

1. Reduction in Progression of Kidney Disease: The study showed that treatment with empagliflozin reduced the risk of kidney disease progression or death from cardiovascular causes by 28% compared to placebo. This effect occurred regardless of the presence of diabetes and glomerular filtration rate levels (up to 20 mL/min) and albuminuria.
2. Hospitalizations: A significant reduction in hospitalizations from any cause was observed, with a 14% decrease in relative risk in patients treated with empagliflozin compared to the control group.
3. Study Included Population: Participants included patients with chronic kidney disease with an eGFR between 20 and 45 mL/min/1.73 m², or between 45 and 90 mL/min/1.73 m² with a urinary albumin/creatinine ratio ≥200, demonstrating the efficacy of the drug even in advanced stages of the disease.
4. Safety and Tolerability: Empagliflozin showed a favorable safety profile, with no significant side effects that compromised the tolerability of the treatment.

Clinical implications

The results of the EMPA-KIDNEY study support the inclusion of empagliflozin as a first-line treatment for patients with chronic kidney disease, in line with international guideline recommendations. The ability of this drug to slow the progression of kidney disease and improve cardiovascular outcomes represents a significant step forward in the clinical management of patients suffering from renal failure.

Conclusion

In summary, the EMPA-KIDNEY study confirmed the importance of SGLT2i, particularly empagliflozin, in nephroprotection and management of chronic kidney disease, offering new hope for patients with this condition.

What are the main conclusions of the EMPA-KIDNEY study

The EMPA-KIDNEY study provided significant results regarding the efficacy of the SGLT2 inhibitor empagliflozin in patients with chronic kidney disease (CKD). Here are the main conclusions that emerged from the study:

1. Reduction of Progression of Kidney Disease

Empagliflozin has been shown to reduce the risk of kidney disease progression or death from cardiovascular causes by 28% compared to placebo. This achievement was achieved in a patient population with a wide range of glomerular filtration rates (eGFRs), including patients with eGFRs up to 20 mL/min/1.73 m² and diabetes-free.

2. Efficacy Independent of the Type of Kidney Disease

The efficacy of empagliflozin in slowing the progression of renal failure was independent of the type of primary renal disease. The subgroups analyzed included patients with diabetic kidney disease, glomerulopathies, and renal damage from hypertension, showing similar results in terms of efficacy.

3. Reduction of Hospitalizations

Treatment with empagliflozin led to a 14% reduction in the risk of hospitalizations for any cause, further highlighting the clinical benefits of the drug in addition to renal protection.

4. Stabilization of Renal Function

The analysis showed a significant difference in the annual decline in eGFR in favor of the empagliflozin-treated group, with a reduction in eGFR decline of approximately 1.37 mL/min/1.73 m² per year, representing a 50% relative decrease in the percentage of decline compared to placebo.

5. Safety and Tolerability

Empagliflozin showed a favorable safety profile, with no significant side effects that compromised the tolerability of the treatment. This is particularly important considering the vulnerability of patients with renal impairment.

General Conclusions

In summary, the EMPA-KIDNEY study confirmed the importance of SGLT2i, in particular empagliflozin, in the management of chronic kidney disease, offering new therapeutic options for patients with renal impairment. The ability of this drug to reduce disease progression and improve clinical outcomes underscores its critical role in clinical practice.

What are the clinical implications of the conclusions of the EMPA-KIDNEY study

The EMPA-KIDNEY study provided significant evidence regarding the use of the SGLT2 inhibitor empagliflozin in patients with chronic kidney disease (CKD). His findings have several important clinical implications for the management of CKD and related conditions.

1. Slowing the Progression of Kidney Disease

One of the main clinical implications is that empagliflozin significantly reduces the risk of CKD progression or cardiovascular death by 28% compared to placebo. This suggests that SGLT2i should be considered a critical component of therapy for patients with CKD, regardless of the presence of diabetes, helping to improve long-term outcomes.

2. Efficacy in Different Patient Populations

The study showed that empagliflozin is also effective in patients with very low eGFR (up to 20 mL/min/1.73 m²) and those without diabetes. This expands the indications for the use of empagliflozin to a broader population of patients with CKD, including those with causes other than diabetic nephropathy, such as glomerulopathies and renal damage from hypertension.

3. Reduction of Hospitalizations

Another important implication is the 14% reduction in the risk of hospitalizations for any cause in patients treated with empagliflozin. This suggests that the use of SGLT2i not only improves kidney function but may also contribute to better overall patient stability, reducing the need for hospitalization.

4. Favorable Safety Profile

Empagliflozin showed a favorable safety profile, with no significant side effects that compromise the tolerability of the treatment. This makes SGLT2i an attractive treatment choice for patients with CKD, who often have comorbidities and may be vulnerable to adverse drug effects.

5. Integration into Clinical Guidelines

The evidence from the EMPA-KIDNEY study supports the inclusion of SGLT2i in clinical guidelines for the management of CKD. Recent recommendations suggest that these drugs should be used in all patients with chronic kidney disease to minimize the risk of progression to end-stage renal failure.

How empagliflozin affects the progression of chronic kidney disease

Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has been shown to have a significant impact on the progression of chronic kidney disease (CKD) according to results from the EMPA-KIDNEY study. Here is an analysis of the main findings and clinical implications.

Key Results of the EMPA-KIDNEY Study

1. Reduction in Progression of Kidney Disease: The study showed that the use of empagliflozin led to a 28% reduction in the risk of CKD progression or death from cardiovascular causes compared to placebo. This effect has been observed in a population of patients with varying degrees of renal impairment, including patients with diabetic and non-diabetic kidney disease.
2. Efficacy Independent of Kidney Disease Type: The analysis showed that empagliflozin’s efficacy in slowing the progression of kidney disease was similar across different subgroups, regardless of the cause of CKD, suggesting that empagliflozin may be useful for a wide range of patients with kidney failure.
3. eGFR slope: During follow-up, a significant difference in eGFR slope was observed between the empagliflozin and placebo groups, with a reduction in eGFR decline of approximately 1.37 mL/min/1.73 m² per year, representing a 50% relative decrease in decline rate.
4. Hospital Admissions: Treatment with empagliflozin also led to a 14% reduction in hospitalizations for any cause, further highlighting the clinical benefits of the drug in addition to kidney protection.

Clinical implications

• Standard Treatment: Results from the EMPA-KIDNEY study support the inclusion of SGLT2i as part of standard therapy for patients with chronic kidney disease. International guidelines now recommend the use of empagliflozin not only in diabetic patients but also in those without diabetes, expanding therapeutic indications.
• Improved Prognosis: The use of empagliflozin could significantly improve the prognosis of nephropathic patients, delaying the need for dialysis or renal transplantation and reducing the risk of associated cardiovascular events.
• Innovative Therapeutic Strategies: The introduction of empagliflozin marks a shift in therapeutic strategies for the management of CKD, shifting the focus from an approach based solely on controlling risk factors to one that includes specific drugs that can modify the course of the disease5.

What are the main kidney diseases that participated in the EMPA-KIDNEY study

The EMPA-KIDNEY study involved patients with different kidney diseases, highlighting the efficacy of the SGLT2 inhibitor empagliflozin in slowing the progression of chronic kidney disease (CKD). The main kidney diseases participating in the study include:

1. Diabetic kidney disease (DKD): Approximately 31.1% of study participants had diabetic kidney disease, a common condition in patients with type 2 diabetes.
2. Glomerular disorders: Another 25.3% of patients had glomerular disorders, which may include conditions such as glomerulonephritis and nephrotic syndrome.
3. Kidney Injury from Arterial or Nephrovascular Hypertension: Approximately 21.9% of participants had kidney damage secondary to arterial hypertension or nephrovascular disease.
4. Other Causes or Unknown Etiology: The remaining 21.8% of patients had kidney disease of other origins or with unknown etiology.

What are the cardiovascular benefits of empagliflozin according to the EMPA-KIDNEY study

According to the results of the EMPA-KIDNEY study, the SGLT2 inhibitor empagliflozin has been shown to have significant cardiovascular benefits for patients with chronic kidney disease. Here are the main findings and implications:

1. Reduction of Cardiovascular Mortality

Empagliflozin led to a 28% reduction in the risk of death from cardiovascular causes compared to placebo. This finding is particularly significant, given that cardiovascular mortality is a critical issue in patients with renal impairment.

2. Reduction of Cardiovascular Events

Treatment with empagliflozin also showed a reduced risk of major adverse cardiovascular events (MACE), which include cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. Although the EMPA-KIDNEY study focused more on the progression of kidney disease, the data suggest that the drug also offers benefits in terms of cardiovascular health.

3. Hospitalizations for Heart Failure

Another important finding was a 14% reduction in the risk of hospitalisations for any cause, including heart failure-related events. This is crucial as patients with CKD are at high risk of heart failure.

4. Efficacy Independent of the Presence of Diabetes

The cardiovascular benefits of empagliflozin have been observed regardless of the presence of diabetes and glomerular filtration rate levels, making the drug useful even for non-diabetic patients with chronic kidney disease.

5. Potential mechanisms

The mechanisms underlying the observed cardiovascular benefits are not fully understood, but could be attributed to pleiotropic effects related to SGLT2 inhibition, such as reduced blood pressure, weight loss, and improved arterial stiffness.

How the group of patients with glomerulopathies performed in the EMPA-KIDNEY study

In the context of the EMPA-KIDNEY study, the group of patients with glomerulopathies showed significant results regarding the efficacy of the SGLT2 inhibitor empagliflozin in slowing the progression of kidney disease. Here are the main details:

1. Composition of the Group

Overall, the study enrolled 6609 patients with chronic kidney disease (CKD), of whom approximately 1669 (25.3%) had glomerular disease. These patients received empagliflozin or placebo to evaluate the effects of treatment on CKD progression.

2. Outcomes of Kidney Disease Progression

The analysis revealed that in the empagliflozin group, progression of kidney damage occurred in 384 (11.6%) of patients, compared to 504 (15.2%) in the placebo group. This results in a hazard ratio (HR) of 0.71 (95% CI 0.62-0.81), indicating a significant reduction in the risk of disease progression in patients with glomerulopathies treated with empagliflozin.

3. Effect on eGFR Decline

Treatment with empagliflozin led to a significant difference in the annual decline in eGFR between the two groups. Specifically, the decline in eGFR in the empagliflozin group was 1.37 mL/min/1.73 m² per year lower than in the placebo group, representing a 50% relative reduction in decline rate.

4. Independence from the Etiology of the Disease

Crucially, the efficacy of empagliflozin in slowing the progression of CKD was similar across different subgroups of primary kidney disease, including those with glomerulopathies and diabetic kidney disease. This suggests that SGLT2i should be considered part of standard therapy for all patients with CKD to minimize progression to end-stage renal failure.

Conclusion

In summary, patients with glomerulopathies in the EMPA-KIDNEY study benefited significantly from empagliflozin treatment, showing a reduction in the progression of renal disease and an improvement in the stability of renal function. These results support the use of empagliflozin as an effective treatment option for patients suffering from different forms of chronic kidney disease.

What are the possible contraindications of empagliflozin according to the EMPA-KIDNEY study

According to the results of the EMPA-KIDNEY study, the use of empagliflozin has some contraindications and precautions to consider. Here is a summary of the main contraindications and warnings associated with this drug:

1. Impaired Renal Function

• eGFR Less than 20 mL/min: Empagliflozin is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) of less than 20 mL/min/1.73 m². This is due to the fact that the drug requires some kidney function to exert its therapeutic effect.
• Discontinuation of Treatment: If eGFR consistently falls below 45 mL/min/1.73 m², empagliflozin treatment should be discontinued.

2. Risk of Volume Depletion

• Dehydration and Hypotension: Reactions related to volume depletion (dehydration, hypovolaemia or hypotension) have been reported in a small number of treated patients. The incidence was higher in elderly patients, particularly those aged 75 years and older.

3. Genital and Urinary Infections

• Genital infections: The use of empagliflozin has been associated with an increased risk of genital infections, such as vulvovaginitis in women and balanitis in men. These infections occurred more frequently in patients with a history of recurrent infections.
• Urinary infections: Although the association with urinary infections has not been as obvious as with genital infections, it is important to monitor patients for any signs of infection.

4. Diabetic Ketoacidosis

• Risk of Ketoacidosis: There have been reported cases of diabetic ketoacidosis in patients treated with SGLT2 inhibitors, including empagliflozin. This risk is particularly relevant in the first months of treatment and can occur even in the absence of marked hyperglycemia.

5. Precautions in Elderly Patients

• In elderly patients, although no dose adjustment is required, it is essential to assess renal function and the risk of volume depletion prior to initiation of therapy.

Conclusion

In summary, while empagliflozin has demonstrated significant benefits in managing chronic kidney disease and reducing cardiovascular events, it is essential to consider the contraindications and precautions associated with its use. It is crucial to monitor patients closely to avoid potential complications.

Empagliflozin is also effective in patients with renal insufficiency due to arterial hypertension

Empagliflozin has also been shown to be effective in patients with renal insufficiency from arterial hypertension, as evidenced by the EMPA-KIDNEY study. Here are the highlights regarding the effectiveness of empagliflozin in this context:

1. Efficacy in Patients With Kidney Damage from Hypertension

• Trial Participation: In the EMPA-KIDNEY trial, approximately 21.9% of participants had kidney injury attributable to high blood pressure or vascular kidney disease. This group benefited from empagliflozin intervention.
• Reduction in Progression of Kidney Disease: The analysis showed that the effect of empagliflozin on decline in glomerular filtration rate (eGFR) was similar among patients with different etiologies of kidney disease, including those with renal impairment from hypertension. The hazard ratio (HR) for progression of renal impairment was 0.71, indicating a significant reduction in risk.

Empagliflozin can be used in combination with other therapies for renal failure

Empagliflozin can be used in combination with other therapies for kidney failure, and the results of the EMPA-KIDNEY study support this practice. Here is a detailed analysis of the implications and therapeutic combinations:

1. Use in Combination with Other Drugs

• Combination Therapy: Empagliflozin has been shown to be effective when used in combination with other medications to treat diabetes, such as metformin, sulfonylureas, and insulin. This approach is useful for optimizing glycemic control in diabetic patients who also have kidney failure.
• Reduced Risk of Hypoglycemia: When empagliflozin is used in combination with sulfonylureas or insulin, a reduction in the dose of these drugs may be necessary to minimize the risk of hypoglycemia. This is particularly important in patients with impaired kidney function, where the risk of side effects may increase.

2. Nephroprotective efficacy

• Results of the EMPA-KIDNEY Study: The study showed that empagliflozin not only slowed the progression of chronic kidney disease, but also offered significant cardiovascular benefits. This makes empagliflozin an advantageous treatment choice to combine with other therapies for the management of CKD and associated comorbidities.
• Independent of Kidney Disease Cause: The results indicate that the efficacy of empagliflozin in slowing the progression of kidney disease is similar among patients with different etiologies, including those with kidney damage from hypertension or diabetic kidney disease.

3. Clinical Recommendations

• International Guidelines: KDIGO guidelines recommend the use of SGLT2i as empagliflozin as first-line treatment for chronic kidney disease, regardless of the presence of diabetes. This supports the idea of using empagliflozin in combination with other therapies to maximize clinical benefits.
• Renal Function Monitoring: It is critical to monitor renal function regularly in patients receiving empagliflozin, especially if they are on combination therapy. Discontinuation of the drug is recommended if the eGFR falls below 45 mL/min/1.73 m².

What are the main factors that affect the effectiveness of empagliflozin

The efficacy of empagliflozin, a sodium-glucose co-transporter type 2 (SGLT2) inhibitor, may be affected by several factors. Here are the main elements that determine the effectiveness of this drug:

1. Renal function

• Glomerular Filtration: Empagliflozin requires some renal function to exert its effect. It is effective in patients with normal eGFR (estimated glomerular filtration rate) or mild renal impairment, but should not be used in patients with eGFR consistently below 45 mL/min/1.73 m². The efficacy of the drug decreases significantly below this threshold, making it necessary to discontinue treatment in such cases.

2. Cardiovascular comorbidities

• Heart Failure: Empagliflozin has demonstrated significant benefit in patients with heart failure, both with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The presence of heart failure may potentiate the positive effects of the drug on cardiovascular mortality and adverse events.

3. Concomitant treatment

• Background Therapies: The efficacy of empagliflozin does not appear to be affected by optimized medical therapy, including drugs such as sacubitril/valsartan. This suggests that empagliflozin may have an additive effect when used in combination with other therapies recommended for the management of heart failure and renal disease.

4. Type of Diabetes

• Type 2 diabetes: Empagliflozin is particularly effective in patients with type 2 diabetes, helping to improve glycemic control and reduce the risk of cardiovascular and kidney complications. However, its effectiveness has also been demonstrated in non-diabetic patients with renal impairment.

5. Age of the Patient

• Elderly: In elderly patients, the use of empagliflozin should be carefully evaluated because of the increased risk of adverse reactions, such as dehydration and hypotension. Although no dose adjustment is necessary, it is important to monitor renal function and the risk of volumetric depletion.

6. Drug interactions

• Concomitant Medications: Concomitant use of empagliflozin with other medications may affect its effectiveness. For example, co-administration with UGT enzyme inducers may reduce the efficacy of the drug. On the other hand, some inhibitors may increase plasma concentrations of empagliflozin, but these changes have not been considered clinically relevant.

Conclusion

In summary, the efficacy of empagliflozin is influenced by various factors including renal function, the presence of cardiac comorbidities, concomitant therapies, the type of diabetes, the age of the patient, and drug interactions. These elements must be considered in clinical practice to optimize treatment and maximize benefits for patients.

What are the differences between dapagliflozin and empagliflozin

Dapagliflozin and empagliflozin are both sodium-glucose co-transporter type 2 (SGLT2) inhibitors used in the treatment of type 2 diabetes and for the management of chronic kidney disease. Although they share many characteristics, there are significant differences between the two drugs:

1. Cardiovascular Efficacy

• Empagliflozin: The EMPA-REG OUTCOME study demonstrated that empagliflozin reduced cardiovascular mortality by 38% and hospitalization for heart failure by 35% in patients with type 2 diabetes and pre-existing cardiovascular disease. In addition, it showed a 14% reduction in the risk of major cardiovascular events (MACE) compared to placebo.
• Dapagliflozin: Dapagliflozin has also demonstrated cardiovascular benefits, as evidenced in the DAPA-HF study, which showed a significant reduction in the risk of hospitalization for heart failure and cardiovascular mortality in patients with heart failure, both diabetic and non-diabetic. However, specific data on cardiovascular mortality were not as marked as for empagliflozin.

2. Therapeutic indications

• Empagliflozin: It is approved for the treatment of type 2 diabetes and has received specific guidance for reducing the risk of cardiovascular events in patients with known cardiovascular disease.
• Dapagliflozin: In addition to the treatment of type 2 diabetes, dapagliflozin has been approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF), even in patients without diabetes.

3. Security Profile

• Both drugs have a favorable safety profile, but there are some differences in the types of adverse effects reported. For example, dapagliflozin has been associated with a slight increase in urinary infections compared to empagliflozin, although both drugs have a similar risk for diabetic ketoacidosis and serious renal events.

4. Selectivity and Mechanism of Action

• Selectivity: Dapagliflozin is known to be more selective for SGLT2 than SGLT1, with a selectivity of more than 1400-fold. Empagliflozin has similar selectivity, but differences in pharmacokinetics may affect clinical efficacy and side effects.

5. Glycemic and Metabolic Response

• Both drugs have been shown to reduce glycated hemoglobin (HbA1c) levels in a similar way, but empagliflozin may have a slightly greater impact on weight loss and blood pressure reduction.

Conclusion

In summary, while dapagliflozin and empagliflozin belong to the same therapeutic class and share many indications and mechanisms of action, there are significant differences in their cardiovascular efficacy, specific therapeutic indications, and safety profiles. The choice between the two drugs may depend on the patient’s clinical characteristics and specific therapeutic needs.

What are the main side effects of dapagliflozin compared to empagliflozin

Side Effects of Dapagliflozin and Empagliflozin: Comparison

Dapagliflozin and empagliflozin, both sodium-glucose co-transporter type 2 (SGLT2) inhibitors, have similar side effects, but there are some significant differences in their incidence and nature. Here is a detailed comparison of the main side effects associated with each drug:

1. Genital and Urinary Infections

• Dapagliflozin:
  • Genital infections were reported in 4.8% of patients treated with dapagliflozin. An increased incidence of urinary infections was observed, with a rate of approximately 5.7% in patients treated with dapagliflozin 10 mg and 4.3% with dapagliflozin 5 mg compared to 3.7% in patients treated with placebo.
• Empagliflozin:
  • Genital infections occurred in 4.1% of patients treated with empagliflozin. Although the incidence is similar to that of dapagliflozin, the risk associated with empagliflozin has been reported to be threefold compared to placebo or other hypoglycaemic agents (OR=3.31).

2. Volume Depletion

• Dapagliflozin:
  • Reactions related to volume depletion (dehydration, hypovolaemia or hypotension) were reported in 0.8% of subjects treated with dapagliflozin.
• Empagliflozin:
  • The incidence of volume depletion-related events was 0.5%, slightly lower than with dapagliflozin.

3. Diabetic Ketoacidosis

• Both drugs have been associated with cases of diabetic ketoacidosis (DKA), although there has been no significant difference between the two in terms of incidence. It is important to note that DKA can occur even in the absence of marked hyperglycemia.

4. Effects on the Cardiovascular System

• Both drugs demonstrated cardiovascular benefits without a significant increase in the risk of adverse cardiovascular events. However, dapagliflozin showed a reduction in all-cause mortality of 17%, while empagliflozin showed a reduction in cardiovascular mortality of 38% in specific studies.

5. Other Side Effects

• Both drugs can cause side effects such as itching and increased urination. However, the frequency and severity can vary from patient to patient and based on individual medical history.

Conclusion

In summary, dapagliflozin and empagliflozin have similar side effect profiles but with some significant differences in their incidence. Both drugs show a good overall safety profile, but it is important to monitor patients for potential adverse effects and manage pre-existing conditions that could increase the risk of complications.

Therapeutic indications

• Dapagliflozin:
  • It is approved for the treatment of type 2 diabetes, heart failure, and chronic kidney disease.
• Empagliflozin:
  • It is approved for the treatment of type 2 diabetes, with specific indications for reducing the risk of cardiovascular events in patients with known cardiovascular disease.

3. Security Profile

Both drugs have similar side effects, such as urinary and genital infections, but the frequency can vary. For example, dapagliflozin showed a slightly higher risk of urinary infections than empagliflozin.

In which patients is dapagliflozin more suitable for use than empagliflozin?

The use of dapagliflozin over empagliflozin may be more indicated in certain patient populations, particularly with regard to cardiovascular and renal conditions. Here is a summary of situations in which dapagliflozin might be preferred:

1. Heart Failure with Reduced Ejection Fraction (HFrEF)

• Dapagliflozin: Dapagliflozin has been shown to significantly reduce the risk of hospitalization for heart failure and cardiovascular mortality in patients with HFrEF, as evidenced in the DAPA-HF study. This study included patients with NYHA II-IV functional class and showed a 26% reduction in the primary endpoint, which included hospitalization for heart failure or cardiovascular death. The benefits were observed regardless of the presence of diabetes .
• Empagliflozin: Empagliflozin also showed efficacy in patients with HFrEF, but the specific evidence for cardiovascular mortality was less marked than for dapagliflozin.

2. Patients with Renal Impairment

• Dapagliflozin: It is approved for the treatment of chronic kidney disease (CKD) regardless of the presence of diabetes. It is particularly indicated in patients with eGFR ≥ 30 mL/min/1.73 m². Its efficacy has also been demonstrated in populations with moderate renal impairment.
• Empagliflozin: Although empagliflozin is also effective in patients with CKD, it is not recommended for use in patients with eGFR < 20 mL/min/1.73 m². However, it has shown significant benefits in renal and cardiovascular protection.

3. Diverse populations

• Dapagliflozin: May be more indicated in patients with acute or chronic heart failure, especially if they have more severe symptoms (NYHA III-IV), as data suggest that patients in these classes may benefit more from treatment.
• Empagliflozin: Although useful, it may be more indicated in patients with preserved ejection fraction (HFpEF), as evidenced in the EMPEROR-Preserved study, where it showed positive effects on quality of life and reduced hospitalizations.

Conclusion

In summary, dapagliflozin is particularly indicated for patients with reduced ejection fraction heart failure and chronic kidney disease, while empagliflozin may be preferred in specific settings such as heart failure with preserved ejection fraction. The choice between the two drugs should be based on the patient’s clinical characteristics and the comorbidities present.

How dapagliflozin and empagliflozin affect fasting blood glucose

Effects on Fasting Blood Glucose

1. Dapagliflozin:
   • Clinical studies have shown that dapagliflozin reduces fasting blood glucose (FPG) and glycated hemoglobin (HbA1c) levels significantly. In one study, a mean reduction in HbA1c of approximately 1.47% and a decrease in fasting blood glucose of approximately 28 mg/dL were observed. In addition, the drug also demonstrated a positive effect on patients with moderate renal impairment, showing a greater reduction in HbA1c in patients with eGFR > 90 mL/min/1.73 m² than in those with eGFR < 60 mL/min/1.73 m².
2. Empagliflozin:
   • Empagliflozin has also been shown to reduce fasting blood glucose levels, although the effect may be less pronounced than dapagliflozin in some studies. In clinical trials, empagliflozin resulted in a reduction in HbA1c of approximately 0.4 to 0.5%, with a negligible effect on fasting blood glucose in some populations. However, it has been observed that empagliflozin may have a more relevant impact on mean blood glucose rather than fasting blood glucose specifically.

Effects Comparison

• Glycosuria: Both drugs increase urinary excretion of glucose (glycosuria), which contributes to lower blood sugar. However, dapagliflozin showed a more consistent effect on glycosuria and lowering fasting blood glucose compared to empagliflozin.
• Insulin Requirements: Both drugs may contribute to a decrease in insulin requirements, but dapagliflozin has shown a more significant reduction in prandial insulin requirements in some studies.

Conclusion

In summary, both dapagliflozin and empagliflozin are effective in reducing fasting blood glucose and glycated hemoglobin in patients with type 2 diabetes. However, dapagliflozin tends to show more marked effects on fasting blood glucose and overall glycemic control than empagliflozin. The choice between the two drugs should consider the individual characteristics of the patient and the specific therapeutic needs.

What are the main clinical trials of SGLT2 in veterinary medicine

1. European Clinical Study on Velagliflozin

• Objective : To evaluate the safety and efficacy of velagliflozin (marketed as Senvelgo) in diabetic cats.
• Description : Cats were treated with 1 mg/kg velagliflozin orally once daily and compared with a control group treated with porcine insulin administered twice daily.
• Results : After 45 days, the treatment success rate in the velagliflozin group was 53.7%, compared to 41.9% for the insulin group. More than 80% of cats treated with velagliflozin showed improvements in glycemic parameters as early as the seventh day. The most common side effects included diarrhea (37.7%) and bladder inflammation (21.3%).

2. U.S. Clinical Study of Velagliflozin

• Objective: To evaluate the safety and efficacy of velagliflozin in cats with newly diagnosed diabetes and those previously treated with insulin.
• Results : 88.4% of cats treated with velagliflozin met criteria for treatment success at day 30. Efficacy assessment was based on clinical signs and glycaemic parameters.

3. Mechanism of Action and Benefits

• Velagliflozin works by inhibiting the SGLT2 transporter, increasing glucose excretion in the urine and reducing blood glucose levels. This effect was observed within one week of starting treatment.

4. Clinical Considerations

• Veterinarians have noted that the use of velagliflozin can improve quality of life in diabetic cats, with an improvement reported in 81% of cases by owners. However, it is important to monitor cats for possible side effects and manage pre-existing conditions.

Conclusion

The use of the SGLT2 inhibitor such as velagliflozin represents a promising therapeutic option for the treatment of diabetes mellitus in cats, showing favorable results compared to traditional insulin therapy. Clinical trials suggest that these drugs may offer an effective and well-tolerated alternative for disease management.